nostic testing to rule out other possible causes of
the symptoms.
Treatment Options and Outlook
Antihistamine medications are the most effective
intervention early in the onset of a type I hyper-
sensitivity reaction, the classic allergic reaction.
These medications block histamine receptors on
cell membrane surfaces, effectively breaking the
chain reaction effect of the immune response. The
longer the hypersensitivity reaction has been
under way, the less effective antihistamine med-
ications are because the reaction moves beyond
histamine release and binding. Treatment for ana-
phylactic symptoms is injection with EPINEPHRINE, a
potent NEUROTRANSMITTERand HORMONEthat effec-
tively halts the immune response. Doctors reserve
epinephrine for life-threatening hypersensitivity
reactions because the drug has numerous and sig-
nificant effects on cardiovascular and pulmonary
function.
CORTICOSTEROID MEDICATIONS are effective for
severe type I reactions and type II, III, and IV reac-
tions. Other IMMUNOSUPPRESSIVE MEDICATIONSsuch
as methotrexate and cyclosporine act through dif-
ferent mechanisms to interrupt the immune
response. DISEASE-MODIFYING ANTIRHEUMATIC DRUGS
(DMARDS) use various mechanisms to achieve simi-
lar results. MONOCLONAL ANTIBODIES (MABS)are
showing great promise for treating hypersensitiv-
ity reactions in some people. The appropriate
treatment selections depend on the type and
severity of the hypersensitivity reaction and any
other health conditions the person may also have.
270 The Immune System and Allergies
TREATMENT OPTIONS FOR HYPERSENSITIVITY REACTION
Treatments Effects Effective for Type of Reaction
ANTIHISTAMINE MEDICATIONS block HISTAMINEbinding type I
CORTICOSTEROID MEDICATIONS suppress COMPLEMENT CASCADE, ANTIBODYactivation, type II, type III, type IV
and eosinophil production type I when severe or
suppress mast cell release of histamine, LEUKOTRIENES, nonresponsive to other treatment
and PROSTAGLANDINS
DISEASE-MODIFYING suppress various immune response pathways type III
ANTIRHEUMATIC DRUGS(DMARDS)
EPINEPHRINEinjection stop the immune response type I when severe or anaphylactic
immunosuppressive agents suppress various immune response pathways type III and type IV
other than corticosteroids
leukotriene receptor block leukotriene binding type I when ASTHMApresent
antagonist medications
MAST CELLstabilizers prevent degranulation within mast cells to block the type I when asthma present
release of histamine, leukotrienes, and prostaglandins
MONOCLONAL ANTIBODIES block antibody–ANTIGENbinding type I when asthma present
(MABS) type III and type IV
NONSTEROIDAL ANTI-INFLAMMATORY block the actions of prostaglandins type III
DRUGS(NSAIDS)